Abstract
The tumor suppressor p53 plays a crucial role in maintaining the genetic integrity of the cell and in suppressing cell transformation. Its cellular levels are usually low and rise substantially in response to DNA damage. Although research on p53 induction following DNA damage has mainly focused on the post-translational modification of p53 by Mdm2, it is known that protein translation also contributes to p53 induction. However, the mechanisms underlying translational regulation of the p53 protein in response to DNA damage are still poorly understood. We show that p53 synthesis increases dramatically in MCF-7 cells treated with etoposide. Interestingly, this increase is accompanied by an increase in the association of the translation initiation factor eIF-4E with its binding protein 4E-BP1, an inhibitor of cap-dependent protein translation. We further identified an internal ribosomal entry site (IRES) located in the 5′-untranslated region of the p53 transcript, that is capable of driving the cap-independent translation of a downstream cistron encoding Firefly luciferase in a dicistronic expression vector. Moreover, we found that the activity of the IRES element increases in response to etoposide-induced DNA damage in MCF-7 cells. These findings provide a novel mechanism for the regulation of p53 translation in response to DNA damage.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Fu L, Benchimol S . (1997). EMBO J 16: 4117–4125.
Fu L, Ma W, Benchimol S . (1999). Oncogene 18: 6419–6424.
Giaccia AJ, Kastan MB . (1998). Genes Dev 12: 2973–2983.
Gingras AC, Raught B, Sonenberg N . (1999). Annu Rev Biochem 68: 913–963.
Hellen CU, Sarnow P . (2001). Genes Dev 15: 1593–1612.
Holcik M . (2004). Curr Cancer Drug Targets 4: 299–311.
Holcik M, Lefebvre C, Yeh C, Chow T, Korneluk RG . (1999). Nat Cell Biol 1: 190–192.
Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW . (1991). Cancer Res 51: 6304–6311.
Komar AA, Hatzoglou M . (2005). J Biol Chem 4: 4.
Kumar V, Sabatini D, Pandey P, Gingras AC, Majumder PK, Kumar M et al. (2000). J Biol Chem 275: 10779–10787.
Lawrence Jr JC, Abraham RT . (1997). Trends Biochem Sci 22: 345–349.
Mazan-Mamczarz K, Galban S, Lopez de Silanes I, Martindale JL, Atasoy U, Keene JD et al. (2003). Proc Natl Acad Sci USA 100: 8354–8359.
Miskimins WK, Wang G, Hawkinson M, Miskimins R . (2001). Mol Cell Biol 21: 4960–4967.
Mosner J, Mummenbrauer T, Bauer C, Sczakiel G, Grosse F, Deppert W . (1995). EMBO J 14: 4442–4449.
Mothe-Satney I, Yang D, Fadden P, Haystead TA, Lawrence Jr JC . (2000). Mol Cell Biol 20: 3558–3567.
Mukhopadhyay D, Houchen CW, Kennedy S, Dieckgraefe BK, Anant S . (2003). Mol Cell 11: 113–126.
Pyronnet S, Pradayrol L, Sonenberg N . (2000). Mol Cell 5: 607–616.
Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG et al. (2003). Cancer Res 63: 6221–6228.
Schumacher B, Hanazawa M, Lee MH, Nayak S, Volkmann K, Hofmann R et al. (2005). Cell 120: 357–368.
Sherrill KW, Byrd MP, Van Eden ME, Lloyd RE . (2004). J Biol Chem 279: 29066–29074.
Spriggs KA, Bushell M, Mitchell SA, Willis AE . (2005). Cell Death Differ 12: 585–591.
Stoneley M, Paulin FE, Le Quesne JP, Chappell SA, Willis AE . (1998). Oncogene 16: 423–428.
Sullivan NF, Willis AE . (1989). Oncogene 4: 1497–1502.
Takagi M, Absalon MJ, McLure KG, Kastan MB . (2005). Cell 123: 49–63.
Tuck SP, Crawford L . (1989). Mol Cell Biol 9: 2163–2172.
Vogelstein B, Lane D, Levine AJ . (2000). Nature 408: 307–310.
Yang DQ, Kastan MB . (2000). Nat Cell Biol 2: 893–898.
Acknowledgements
We thank Dr Michael B Kastan for the pRST/hUTR-luc-plus vector and for his advice as well as Dr Anne Willis for kindly providing us with the pRF and pREMCVF constructs. We also thank Dr Keith Miskimins and Dr Ronald Lindahl for critical reading of this manuscript. This work was supported by a start-up fund received by D-Q Yang from the University of South Dakota, Sanford School of Medicine.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yang, DQ., Halaby, MJ. & Zhang, Y. The identification of an internal ribosomal entry site in the 5′-untranslated region of p53 mRNA provides a novel mechanism for the regulation of its translation following DNA damage. Oncogene 25, 4613–4619 (2006). https://doi.org/10.1038/sj.onc.1209483
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1209483
Keywords
This article is cited by
-
Prognostic significance of p53, Sox11, and Pax5 co-expression in mantle cell lymphoma
Scientific Reports (2021)
-
SKP2 promotes breast cancer tumorigenesis and radiation tolerance through PDCD4 ubiquitination
Journal of Experimental & Clinical Cancer Research (2019)
-
Genome-wide CRISPR screen identifies ELP5 as a determinant of gemcitabine sensitivity in gallbladder cancer
Nature Communications (2019)
-
Variants of the 5′-terminal region of p53 mRNA influence the ribosomal scanning and translation efficiency
Scientific Reports (2018)
-
DDX3 localizes to the centrosome and prevents multipolar mitosis by epigenetically and translationally modulating p53 expression
Scientific Reports (2017)